ArticleFrontiers in oncology2025

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models.

Ying Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.